Gateway Center operations to expand with sobering center and housing services
Los Lunas ready to break ground on I-25 interchange project
The city said the 24-hour facility will ease pressure on hospitals and connect people to long-term treatment. City councilors also approved a separate contract with the group, Community Bridges, to expand housing and treatment services for men, adding 42 beds. Community Bridges will also run the first responder receiving area.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
Serena Williams reveals she's using weight loss drugs and addresses stigma
Serena Williams is sharing how she took a swing at weight loss drugs. The tennis legend, 43, explained she "hit a wall" she had never encountered before after having her kids in a campaign video for telehealth company Ro. "I was doing everything right — working out, eating clean, following the plan. But my body wasn't responded the way it used to. I knew my body was missing something it needed," she said in the ad. The answer for her, she continued, was GLP-1s. According to the campaign, Williams has lost 31 pounds in 8 months using GLP-1s, though it is unclear which drug she has used. The campaign noted she used another GLP-1 provider before Ro, which currently offers Zepbound, Ozempic, Wegovy and Saxenda. Drugs known as GLP-1 receptor agonists mimic a hormone in the body known as glucagon-like peptide 1, which helps signal fullness to the brain and regulate blood sugar. Ozempic is typically used for diabetes while Saxenda, Wegovy and Zepbound are approved for weight loss. Williams, now a celebrity patient ambassador for Ro, also spoke to the stigma surrounding the popular weight loss drugs. "If you're on GLP-1s too, don't let anybody tel you it's the 'easy way out.' You're not taking a shortcut, you're taking care of yourself, and that takes courage," she said. In an interview with People magazine Thursday, Williams said she feels "really good and healthy." "I feel light physically and light mentally," she told the magazine. "I just can do more. I'm more active. My joints don't hurt as much. I just feel like something as simple as just getting down is a lot easier for me. And I do it a lot faster." This isn't the first famous face to open up about their use of the medications. In 2023, Oprah Winfrey revealed she turned to a weight-loss medication after years of struggling with her weight. Videos on social media showing dramatic transformations have also increased demand in recent years. The medications don't come without risks, however. For example, the most common side effects of Ozempic are nausea, stomach pain, constipation, diarrhea and vomiting, according to the drug's website. Some people have reported severe GI-related issues, including gastroparesis, a paralysis of the stomach also called delayed gastric emptying. This condition is the basis of a lawsuit filed in 2023, which claims the drug makers failed to warn consumers. And long-term, it's unclear how these drugs will affect the body. Trump sounds off on potential security guarantees for Ukraine Creative school lunch ideas for kids who are picky eaters Tennis star Daria Kasatkina embraces new life in Australia ahead of U.S. Open Solve the daily Crossword
Medscape
21 minutes ago
- Medscape
Crush Your Med School Debt: Proven Strategies to Start Now
This transcript has been edited for clarity. Let's talk about student loan debt. Most of us in medicine are carrying six-figure debt, and honestly, it can feel really paralyzing. Here are a few tips to get ahead. First, know your loan type — federal vs private — because repayment options can differ. Second, if you're working at a nonprofit hospital, look into public service loan forgiveness, PSLF, because it can actually wipe out your remaining balance after 10 years of qualifying payments. Third, consider enrolling in an income-driven repayment plan during residency. Keep these payments low and sustainable, and start paying into these qualifying months. Last, use tools or websites that help you create a budget, or even consider consulting a student loan advisor. Honestly, as scary as they are, ignoring your loans makes them even a plan gives you a little bit of control.
Medscape
21 minutes ago
- Medscape
Phone-Based Program Boosts Weight Loss in Breast Cancer
TOPLINE: A telephone-based weight-loss intervention led to clinically significant weight loss in women with stage II/III breast cancer and overweight or obesity, according to a 1-year analysis of a phase 3 study. Although effective across all demographic and racial/ethnic subgroups, the intervention was more effective in postmenopausal and non-Black/non-Hispanic participants. METHODOLOGY: Obesity is associated with increased risks for recurrence, mortality, comorbidities, and poor quality of life in patients with breast cancer. Prior weight-loss studies were small, included mostly non-Hispanic White patients, and used in-person formats that may not be applicable to a broader population. Researchers conducted a secondary analysis of a phase 3 clinical trial (BWEL) involving 3180 women (mean age, 53.4 years) with stage II/III human epidermal growth factor receptor-negative breast cancer and a BMI ≥ 27 who were randomly assigned 1:1 to receive either a 2-year telephone-based weight-loss intervention (n = 1591) plus standard health education materials or health education materials alone (n = 1589; control group). The weight loss intervention promoted weight loss through caloric restriction (1200-1800 kcal/d based on baseline body weight) and increased physical activity (150 min/wk during the first 6 months, increasing to 225 min/wk thereafter). The primary endpoint for this prespecified secondary analysis was weight change at 1 year. TAKEAWAY: At 1 year, participants in the intervention group achieved a mean weight loss of 4.3 kg, equivalent to 4.7% of baseline body weight, whereas those in the control group gained a mean of 0.9 kg or 1.0% of baseline body weight (mean between-group difference, 5.3 kg; P < .001). At 1 year, 46.5% of participants in the intervention group achieved a clinically significant weight loss of at least 5% of baseline weight compared with 14.3% in the control group (P < .001); similarly, 22.5% in the intervention group and 5.0% in the control group lost 10% of baseline body weight (P < .001). Subgroup analyses showed greater weight loss among postmenopausal women (mean difference, 6.37%) than among premenopausal women (mean difference, 4.82%), and less weight loss among Black and Hispanic participants than among participants of other racial and ethnic groups (mean differences, 3.74% and 4.14%, respectively, vs 6.11%). Participants in the weight loss intervention completed a median of 26 out of 30 planned coaching calls during the first year, and weight loss was positively correlated with the number of calls completed (correlation coefficient, 0.57; P = .02); premenopausal women participated in fewer calls than postmenopausal women (median, 25 vs 26; P < .001), and Black and Hispanic women participated in fewer calls than those of other racial and ethnic groups (median, 23 and 22 vs 26; P < .001). IN PRACTICE: These findings 'demonstrate the feasibility of implementing a lifestyle based WLI [weight loss intervention] as a part of breast cancer treatment,' the study authors concluded. 'While BWEL showed successful weight loss on average, it is not clear if the amount achieved will be sufficient to produce meaningful improvement in prognosis,' Anne McTiernan, MD, PhD, University of Washington, Seattle, wrote in an accompanying editorial, further adding that 'trials of weight loss treatments that produce greater degrees of weight loss are also needed in patients with breast cancer, both to determine risk-benefit ratios and to provide treatment options for this population.' SOURCE: The study, led by Jennifer A. Ligibel, MD, Dana-Farber Cancer Institute in Boston, was published online in JAMA Oncology. LIMITATIONS: Over 20% had missing 1-year weight data due to pandemic-related virtual visits, disproportionately among younger, Black, hormone receptor-negative, and lower-income participants. Women in the study were participating in the coaching calls during the collection of weight loss data. Detailed diet and activity data were limited to a subset, precluding full behavioral analyses. DISCLOSURES: The study was supported by grants from the National Cancer Institute of the National Institutes of Health. Additional support was provided to Ligibel by the Susan G. Komen Foundation, Breast Cancer Research Foundation, and American Cancer Society. Several study authors reported receiving grants or personal fees and having other ties with various sources. Additional disclosures are noted in the original article. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
